7
The majority of U.K. centers are unable to provide venovenous extracorporeal membrane oxygenation (VV ECMO) for neonates due to concerns with availability and suitability of dual lumen cannulae. An alternative to be considered... Read More
7 Tag: oxygenation
7 6
Patients with sepsis-induced cardiomyopathy with cardiogenic shock have a high mortality. This study assessed venoarterial extracorporeal membrane oxygenation (VA-ECMO) support for sepsis-induced cardiogenic shock refractory... Read More
10
With great interest we read the article by Convertino et al. discussing potential treatment targets for pharmacological immunomodulation in coronavirus disease 2019 (COVID-19) with acute respiratory distress syndrome (ARDS).... Read More
4
Cardiopulmonary bypass (CPB) is common for most cardiac surgeries. CPB drains blood from the heart and returns it to the proximal systemic circulation allowing perfusion during the operative period. It was pioneered in 1951... Read More
5
With a highly trained multidisciplinary team and a focus on restoring function, it is feasible and safe to deliver early rehabilitation including standing and ambulation to patients on extracorporeal membrane oxygenation... Read More
10
Venoarterial extracorporeal membrane oxygenation (VA ECMO), a form of mechanical circulatory support, had its origins in the operating room as cardiopulmonary bypass and has evolved for use in the intensive care unit and... Read More
8
Extracorporeal membrane oxygenation (ECMO) has been in clinical use for some 40 years, but it is only in the past decade that its application in the treatment of life-threatening circulatory and respiratory failure has truly... Read More
5
Confusion between inhaled versus intravenous routes for pulmonary vasodilators. For optimal clinical benefit (especially regarding oxygenation), these agents must be given via an inhaled route. The misconception that inhaled... Read More
11
Quickly and accurately diagnose and treat the critically ill patient with guidance from the field’s definitive text. Considered the field’s definitive text, Principles of Critical Care offers unmatched coverage... Read More
10
Humanigen, the clinical stage biopharmaceutical company focused on preventing and treating cytokine storm, has reported positive data from the first clinical use of lenzilumab, its humaneered anti-human granulocyte macrophage-colony... Read More
9
The goal of this book is to provide the most up to date information on mechanical ventilation based on current research, evidence based practice and my experiences as a flight paramedic and educator. A comprehensive look... Read More
6
COVID-19 has existed for less than six months, and it is easy to forget how little we know about it. The standard view is that a minority of infected people, who are typically elderly or have preexisting health problems,... Read More
13
The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) poses an unprecedented global healthcare challenge. Severe novel Coronavirus disease (COVID-19) pneumonia frequently causes hypoxemic respiratory failure, manifesting... Read More
15
Recently, novel coronavirus 2019 (nCOV-19) is spreading all around the world causing severe acute respiratory syndrome (SARS-CoV-2) requiring mechanical ventilation in about 5% of infected people. Prone position ventilation... Read More
7
The healthcare burden of the coronavirus disease 2019 (COVID-19) pandemic extends beyond patients who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a retrospective cohort study... Read More
![Between June 18 and Aug 3, 2020, Ministry of Health of the Russian Federation enrolled 76 participants to the two studies (38 in each study). In each study, 9 volunteers received rAd26-S in Phase 1, nine received rAd5-S in phase 1, and 20 received rAd26-S and rAd5-S in Phase 2. Both vaccine formulations were safe and well tolerated. In both Phase 1 and 2 studies of the Sputnik V vaccine all 76 participants developed antibodies to the virus that causes COVID-19. The most common adverse events were pain at injection site (44 [58%]), hyperthermia (38 [50%]), headache (32 [42%]), asthenia (21 [28%]), and muscle and joint pain (18 [24%]). Most adverse events were mild and no serious adverse events were detected. All participants produced antibodies to SARS-CoV-2 glycoprotein. Cell-mediated responses were detected in all participants at day 28, with median cell proliferation of 2·5% CD4+ and 1·3% CD8+ with the frozen formulation, and a median cell proliferation of 1·3% CD4+ and 1·1% CD8+ with the lyophilised formulation. The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants. Further investigation is needed of the effectiveness of this vaccine for prevention of COVID-19.](https://criticalcare.news/wp-content/uploads/from-russia-with-love-sputnik-v-covid-19-vaccine-generated-an-immune-response-100x100.jpg)
